Xencor (XNCR) Share-based Compensation (2013 - 2026)
Xencor's (XNCR) quarterly Share-based Compensation came in at $9.6 million in Q1 2026, down 21.71% year-on-year from $12.2 million in Q1 2025, and down 6.13% on a QoQ basis from $10.2 million in Q4 2025.
Xencor (XNCR) Share-based Compensation (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Share-based Compensation data on file, last reported at $9.6 million in Q1 2026.
- On a quarterly basis, Share-based Compensation fell 21.71% year-over-year to $9.6 million in Q1 2026; TTM through Mar 2026 was $40.6 million, a 24.96% decrease from a year earlier, with the FY2025 full-year figure at $43.2 million, down 18.87% from the prior year.
- Share-based Compensation for Q1 2026 stood at $9.6 million, down from $10.2 million in the prior quarter.
- Over the last five years, Share-based Compensation for XNCR reached as high as $51.3 million in Q4 2023 and fell as low as -$30.0 million in Q4 2022.
- Historically, Share-based Compensation has averaged $11.9 million across 5 years, with a median of $12.3 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 1295.68% in 2022 and fell as far as 1082.08% in 2022.
- Year by year, Share-based Compensation stood at -$30.0 million in 2022, then surged by 270.9% to $51.3 million in 2023, then sank by 75.96% to $12.3 million in 2024, then retreated by 17.41% to $10.2 million in 2025, then declined by 6.13% to $9.6 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $9.6 million in Q1 2026, $10.2 million in Q4 2025, and $10.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | 9.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.56 Mn |
| Mar 31, 2026 | 9.56 Mn |
| Dec 31, 2025 | 10.19 Mn |
| Dec 31, 2025 | 10.19 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 12.21 Mn |
| Mar 31, 2025 | 12.21 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Sep 30, 2024 | 12.34 Mn |
| Sep 30, 2024 | 12.34 Mn |
| Jun 30, 2024 | 17.19 Mn |
| Jun 30, 2024 | 17.19 Mn |
| Mar 31, 2024 | 11.42 Mn |
| Mar 31, 2024 | 11.42 Mn |
| Dec 31, 2023 | 51.29 Mn |
| Dec 31, 2023 | 51.29 Mn |